Paving the Way to Personalized Treatment
Cancer Genetics has developed a number of proprietary tests for difficult-to-diagnose cancers including B-cell neoplasms, urogenital cancers, and HPV-associated cancers. Proprietary test platforms include NGS-based panels, CGH microarrays, and DNA-FISH probes. CGI also offers unique pharmacogenomic testing.
Next-Generation sequencing (NGS) performs massively parallel sequencing of genomes, allowing for the analysis of a significant number of genomic targets with a single test. Critically, NGS allows for the detection of aberrations that may only be present at very low levels, but which may have important clinical relevance for the patient’s diagnosis and prognosis.
Click here to learn more about CGI’s proprietary Focus::NGS®panels.
Fluorescence in situ hybridization (FISH) is used to detect chromosomal aberrations such as DNA copy number changes (gain/loss) and rearrangements (translocation/break apart). FISH is a method of choice for diagnosis, prognosis, and treatment response prediction for a number of hematological and solid tumor cancers.
Click here to learn more about FHACT,® CGI’s FISH-based HPV-Associated Cancer Test.
Microarray based technology assesses a large number of genetic alterations in a single experiment. One application of this technology, known as array-CGH, is utilized to evaluate DNA copy number changes (gains/losses) observed frequently in tumor genomes. CGI has designed disease-specific, targeted microarrays for diagnostic and prognostic purposes in a variety of cancers.
Click here to learn more about MatBA,® CGI’s Array-CGH assay for mature B-cell neoplasms.
Pharmacogenomic testing is becoming increasingly central to the field of personalized medicine. Pharmacogenomic testing assesses biomarkers associated with drug metabolism and is used to help reduce the incidence of adverse drug reactions and predict how an individual patient will respond to a given medication. Pharmacogenomics can help ensure that patients get the right medication and the right dose.
Click here to learn more about CGI’s pharmacogenomic testing services.